EVOQ Therapeutics is developing immunotherapies focused on improving the lives of individuals fighting autoimmune diseases and cancer.
Autoimmune disease occurs when the body’s central immune tolerance system breaks down and fails. This results in T and B cell-mediated destruction of self-tissues and is responsible for many devastating diseases including – Type 1 Diabetes, Celiac disease, Multiple sclerosis and Rheumatoid Arthritis.
EVOQ’s technology unleashes and restores the body’s natural immune tolerance pathways.
Harnessing the human immune system to treat autoimmune disease and cancer can be extremely challenging. Evoking an appropriate immune system response requires a complex set of interactions between the innate and adaptive immune system.
Fortunately, there is one component that plays a central role in orchestrating immune responses.
That central component is dendritic cells (DCs). Also known as a “professional” antigen-presenting cells (APCs), dendritic cells specialize in priming different types of effector T cells - thereby directing the immune system either toward a state of self-tolerance or toward the initiation of protective immune activation.
Compared to other APCs, such as B cells and macrophages, dendritic cells are considered to be the most versatile and efficient APCs because of their unique ability to control both immune tolerance and cell-mediated immune activation. They accomplish this using a mix of signals in the form of cell surface receptors and cytokines.
It is for these reasons that denditric cells have long been an attractive target for immunotherapy to treat autoimmune disease and cancer.
Unfortunately, to date attempts to evoke a truly potent, focused, and sustained response from dendritic cells has produced mixed results.
EVOQ’s breakthrough, proprietary technology unleashes the full potential of dendritic cell mediated immunotherapy.